VisionPoint Advisory Group LLC Acquires 7,771 Shares of Avantor, Inc. (NYSE:AVTR)

VisionPoint Advisory Group LLC boosted its holdings in Avantor, Inc. (NYSE:AVTR) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 156,767 shares of the company’s stock after purchasing an additional 7,771 shares during the period. Avantor makes up 1.1% of VisionPoint Advisory Group LLC’s portfolio, making the stock its 18th largest position. VisionPoint Advisory Group LLC’s holdings in Avantor were worth $3,323,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in AVTR. Creative Planning boosted its position in Avantor by 54.0% during the 3rd quarter. Creative Planning now owns 28,136 shares of the company’s stock valued at $728,000 after buying an additional 9,866 shares during the period. Blue Trust Inc. raised its stake in shares of Avantor by 414.5% during the third quarter. Blue Trust Inc. now owns 7,547 shares of the company’s stock valued at $195,000 after acquiring an additional 6,080 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Avantor during the third quarter worth about $255,000. Tandem Capital Management Corp ADV grew its stake in shares of Avantor by 6.7% in the third quarter. Tandem Capital Management Corp ADV now owns 49,582 shares of the company’s stock worth $1,268,000 after purchasing an additional 3,130 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new stake in shares of Avantor in the 3rd quarter worth approximately $4,874,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. Stifel Nicolaus decreased their price objective on shares of Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a report on Monday, February 10th. Royal Bank of Canada reduced their price target on Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a research note on Monday, February 10th. Morgan Stanley lowered their price objective on Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Raymond James reaffirmed an “outperform” rating and issued a $24.00 target price (down from $26.00) on shares of Avantor in a research report on Monday, February 10th. Finally, Robert W. Baird decreased their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.92.

Avantor Stock Performance

Shares of AVTR stock opened at $17.52 on Friday. The company has a market capitalization of $11.93 billion, a price-to-earnings ratio of 16.84, a price-to-earnings-growth ratio of 1.56 and a beta of 1.28. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.70 and a current ratio of 1.07. Avantor, Inc. has a one year low of $17.14 and a one year high of $28.00. The company’s 50-day moving average is $21.06 and its 200 day moving average is $23.01.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 10.49% and a return on equity of 12.17%. During the same quarter in the previous year, the business earned $0.22 EPS. Sell-side analysts expect that Avantor, Inc. will post 1.06 EPS for the current fiscal year.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.